Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

The world did not end today as predicted, but unfortunately we have to report that development of another potential drug did. Allon Therapeutics Inc. announced 19 December that its drug candidate ...

To clear plaque, lecanemab must activate microglia. Activated microglia turn on DAM genes such as osteopontin. Lecanemab covers Aβ42 protofibrils more densely than does aducanumab. Some scientists ...

Certain mutations in the GBA1 gene are the most common genetic risk factors for Parkinson’s disease; even so, most people with these variants never develop PD. Now, scientists led by Anthony Schapira ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...

Could CAR-T, the immunotherapy that has transformed treatment for some cancers, hold promise for Alzheimer’s? In the February 9 PNAS, scientists led by Jonathan Kipnis at Washington University in St.

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Species: Mouse Genes: LRRK2 Modification: LRRK2: Knock-In Disease Relevance: Parkinson's Disease Strain Name: C57BL/6-Lrrk2 tm4.1Arte Genetic Background: C57BL/6NTac Availability: Available through ...

More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...